Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors)

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 242-251

  Hirokawa, Yumiko ^a   Levitzki, Alexander ^b   Lessene, Guillaume ^c   Baell, Jonathan ^c   Xiao, Yi ^a   Zhu, Hongjian ^a   Maruta, Hiroshi ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c Institute for Medical Research   (Australia)

Author keywords

GL 2003; Neurofibromatosis; PAK1; Pancreatic cancers; PP1; RAS

Indexed keywords

3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AZM 475271; ESTROGEN; FR 901228; GEMCITABINE; GL 2003; KIGAMICIN D; P21 ACTIVATED KINASE 1; PROTEIN CDC42; PROTEIN KINASE INHIBITOR; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAC PROTEIN; RAS PROTEIN;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CODON; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MONOTHERAPY; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; SARCOMA; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; NEUROFIBROMIN 1; NITRILES; PANCREATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; QUATERNARY AMMONIUM COMPOUNDS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845630173     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.018     Document Type: Article

References (24)

1. Bos J. Ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
2. He H., Hirokawa Y., Manser E., Lim L., Levitzki A., Maruta H., et al. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 7 (2001) 191-202
3. Lu J., Kunimoto S., Yamazaki Y., Kaminishi M., and Esumi H. Kigamicin D, a novel anti-cancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci. 95 (2004) 547-552
4. Ueda H., Nakajima H., Hori Y., Goto T., and Okuhara M. Action of FK228, a novel anti-tumor bicyclic depsipeptide produced by C. violaceum #968, on Ha-RAS transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 58 (1994) 1579-1583
5. Sato N., Ohta T., Kitagawa H., Kayahara M., Ninomiya I., Fushida S., et al. FK228, a novel HDAC inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int. J. Oncol. 24 (2004) 679-685
6. Tang Y., Chen Z., Ambrose D., Liu J., Gibbs J.B., Chernoff J., et al. Kinase-deficient PAK1 mutant inhibits RAS transformation of Rat-1 fibroblasts. Mol. Cell. Biol. 17 (1997) 4454-4464
7. He H., Hirokawa Y., Levitzki A., and Maruta H. An anti-RAS cancer potential of PP1, an inhibitor specific for Src family kinases; in vitro and in vivo studies. Cancer J. 6 (2000) 243-248
8. He H., Hirokawa Y., Gazit A., Yamashita Y., Mano H., Kawakami Y., et al. The Tyr-kinase inhibitor AG 879, that blocks the ETK-PAK1 interaction, suppresses RAS-induced PAK1 activation and malignant transformation. Cancer Biol. Ther. 3 (2004) 96-101
9. Hirokawa Y., Arnold M., Nakajima H., Zalcberg J., and Maruta H. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol. Ther. 4 (2005) 956-960
10. Hirokawa Y., Nakajima H., Hanemann O., Kurtz A., Frahm S., Mautner V., et al. Signal therapy of NF1-deficient tumor xenoograft in mice by the anti-PAK1 drug FK228. Cancer Biol. Ther. 4 (2005) 379-381
11. Davies H., Bignell G., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 766 (2002) 1-6
12. Y. Hirokawa, M. Arnold, H. Nakajima, H. Maruta, Signal therapy of cancers: blocking PAK pathways by FK228, Proceedings of the Miami Winter Symposium, vol. 16, 2005, p. 64.
13. Yau C., Wheeler J., Sutton K., and Hedley D. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI-3 kinase/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res. 65 (2005) 1497-1503
14. Xiao J., Hunag Y., Dai Z., Sadee W., Chen J., Liu S., et al. Chemoresistance to FK228 is mediated by reversible MDR1 induction in human cancer cell lines. J. Pharmacol. Exp. Ther. 314 (2005) 467-475
15. Sawakawa Y., Naoe Y., Inoue T., Sawakawa T., Matsuo M., Manda T., et al. Effects of FK228, a novel HDAC inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett. 195 (2003) 161-168
16. Sawa H., Murakami H., Kumagai M., Nakasato M., Yamauchi S., Matsuyama N., et al. HDAC inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol. 107 (2004) 523-531
17. Duxbury M., Ito H., Zinner M., Ashley S., and Whang E. Inhibition of Src Tyr-kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adeno-carcinoma cells. Clin. Cancer Res. 10 (2004) 2307-2318
18. Yezhelyev M., Koehl G., Guba M., Brabletz T., Jauch K.W., Ryan A., et al. Inhibition of Src Tyr-kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 10 (2004) 8028-8036
19. Bagheri-Yarmand R., Vadlamudi R., Wang R.A., Mendelsohn J., and Kumar R. VEGF up-regulation via PAK1 signaling regulates heregulin-beta1-mediated angiogenesis. J. Biol. Chem. 275 (2000) 39451-39457
20. Kiosses W., Hood J., Yang S., Gerritsen M., Cheresh D., Alderson N., et al. A dominant negative PAK1 peptide inhibits angiogenesis. Circ. Res. 90 (2002) 697-702
21. Nheu T., He H., Hirokawa Y., Tamaki K., Burgess A.W., Florin L., et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family, selectively block the growth of RAS transformants. Cancer J. 8 (2002) 328-336
22. Krapcho A.P., and Kuell C.S. Synth. Commun. 20 16 (1990) 2559-2564
23. Sifferlen T., Rueping M., Gademann K., Jaun B., and Seebach D. Helv. Chim. Acta 82 (1999) 2067-2093
24. US Patent 02,749,353.